Anti-TGF beta 1 antibody [9016.2] (ab10517)

Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab10517 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ELISA
Inhibition Assay
WB
  • Application notesWB: Use at a concentration of 1 - 2 µg/ml. Determined for 20 ng recombinant human TGF Beta 1 under non-reducing conditions. Predicted molecular weight: 47 kDa for the unprocessed precursor; 25 kDa for the mature protein.
    ELISA: Use at a concentration of 2 - 4 µg/ml. Determined for 9 pg/ml of recombinant human TGF beta 1.
    Inhib: Use at a concentration of 0.3 - 1 µg/ml.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionMultifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
    • Tissue specificityHighly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
    • Involvement in diseaseDefects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
    • Sequence similaritiesBelongs to the TGF-beta family.
    • Post-translational
      modifications
      Glycosylated.
      The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
    • Cellular localizationSecreted > extracellular space > extracellular matrix.
    • Target information above from: UniProt accession P01137 The UniProt Consortium
      The Universal Protein Resource (UniProt) in 2010
      Nucleic Acids Res. 38:D142-D148 (2010) .

      Information by UniProt
    • Database links
    • Alternative names
      • Camurati Engelmann disease antibody
      • CED antibody
      • Diaphyseal dysplasia 1 progressive antibody
      • DPD1 antibody
      • LAP antibody
      • Latency-associated peptide antibody
      • TGF beta 1 antibody
      • TGF beta antibody
      • TGF beta 1 protein antibody
      • TGF-beta 1 protein antibody
      • TGF-beta-1 antibody
      • TGF-beta-5 antibody
      • TGF-beta1 antibody
      • TGFB 1 antibody
      • TGFB antibody
      • Tgfb-1 antibody
      • TGFB1 antibody
      • TGFB1_HUMAN antibody
      • TGFbeta antibody
      • TGFbeta1 antibody
      • Transforming Growth Factor b1 antibody
      • Transforming Growth Factor beta 1 antibody
      • Transforming growth factor beta 1a antibody
      • transforming growth factor beta-1 antibody
      • transforming growth factor, beta 1 antibody
      see all

    References for Anti-TGF beta 1 antibody [9016.2] (ab10517)

    This product has been referenced in:
    • Soller EC  et al. Common features of optimal collagen scaffolds that disrupt wound contraction and enhance regeneration both in peripheral nerves and in skin. Biomaterials 33:4783-91 (2012). WB ; Rat . Read more (PubMed: 22483241) »
    • Wang L  et al. Concentration-dependent effects of transforming growth factor ß1 on corneal wound healing. Mol Vis 17:2835-46 (2011). Inhibition Assay ; Human . Read more (PubMed: 22128231) »

    See all 4 Publications for this product

    Product Wall

    Application Western blot
    Sample Rat Tissue lysate - whole (Peripheral nerve wound)
    Loading amount 15 µg
    Specification Peripheral nerve wound
    Gel Running Conditions Reduced Denaturing
    Blocking step Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Dec 11 2008

    Thank you for your enquiry. In general, a neutralizing antibody is defined to be an antibody that prevents a virus from infecting a cell, usually by blocking receptors on the cells or virus. A blocking antibody is defined to be an antibody that combine...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"